While the 21st century has been bumpy, it has also ushered in monumental scientific and technological breakthroughs that have ...

Leading synthetic biologists have shared hard-won lessons from their decade-long quest to build the world's first synthetic ...

Unacademy's valuation has dropped by over 85% from its pandemic-era peak price tag of $3.5 billion, its founder said.

The last two weeks have been packed with collaborations for unveiling innovative products and kick-starting prosperous partnerships. From quantifying His-tagged proteins and characterizing mutations ...

LONDON, Oct 27 (Reuters) - Swiss drugmaker Novartis (NOVN.S), opens new tab on Monday defended its $12 billion deal to acquire Avidity Biosciences ahead of the U.S. firm getting late-stage data for ...

Novartis NOVN-0.15%decrease; red down pointing triangle is acquiring Avidity Biosciences RNA 0.20%increase; green up pointing triangle in a $12 billion deal that the Swiss drugmaker said would further ...

Novartis staff celebrate the company’s 25 years in San Diego outside the Genomics Institute of the Novartis Research Foundation in Torrey Pines. (Photo courtesy of the company) Swiss pharmaceutical ...

Almost a year after buying Kate Therapeutics, Novartis has scooped up another San Diego-based muscle dystrophy biotech in one of the biggest acquisitions of 2025 so far. The Swiss pharma is paying $12 ...

Swiss drugmaker Novartis on Sunday said it agreed to acquire U.S. biotech firm Avidity Biosciences for about $12 billion in cash, as the company looks to bolster its portfolio of treatments for rare ...

The company’s goal is to bring new treatments to market, with Circular RNA being a vital molecule in cells that can regulate critical biological processes. Crystal Brown, co-founder of biotechnology ...

Nobel Prize winners, from left: Mary Brunkow, senior program manager at the Institute for Systems Biology, Fred Ramsdell, co-founder and chair of Sonoma Biotherapeutic’s scientific advisory board; and ...

In this article, we will look at the top 12 Affordable Biotech Stocks to Invest In Now. On September 4, Mizuho healthcare strategist Jared Holz appeared on CNBC’s ‘Power Lunch’ to talk about the ...